Backed by Norwest.
About the role
The Manager/Senior Manager, Investor Relations & Corporate Communications will provide hands-on execution across a broad range of investor relations and external communications initiatives. This is a writing- and production-intensive role that is ideal for a communications professional who thrives on delivering high-quality work across multiple workstreams.
What they're looking for
- A minimum of 4–8 years of experience in biotech/biopharma corporate communications, science communications, or healthcare public relations, agency and/or in-house experience welcome
- Exceptional writing and editing skills across a range of formats, including press releases, social media content, briefing documents, executive messaging, website copy, and presentations
- Hands-on experience executing corporate social media programs, including content drafting, calendar management, and cross-functional content coordination
- Working knowledge of the clinical development process and familiarity with how pipeline milestones and data readouts drive communications activity
- Experience supporting communications around clinical data disclosures or medical conferences (e.g., ATS, AAD, EADV, ASH, ASCO, ESMO, or equivalent)
- Familiarity with Reg FD principles and social media disclosure considerations in a public company context
More about this role
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA-IPF, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its...
Browse similar: Startup jobs · Boston